GSK acquires rights to prostate-cancer candidate from Syndivia for up to £268 million
Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile
Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile
Subscribe To Our Newsletter & Stay Updated